Nimustine


Full Prescribing Info
Dosage/Direction for Use

Intravenous
Malignant glioma
Adult: As hydrochloride: 2-3 mg/kg or 90-100 mg/m2 as a single dose by slow IV inj at intervals of 6 wk according to haematological response.
Contraindications
Pregnancy and lactation.
Special Precautions
Child. Renal or hepatic impairment, haemorrhagic syndrome, infectious diseases. Monitor blood counts and liver function.
Adverse Reactions
Leukopenia, iron-deficiency anaemia, anorexia, nausea, vomiting, diarrhoea, stomatitis, headache, dizziness, convulsions, weakness, fatigue, haemorrhagic symptoms, interstitial pneumonitis, increased body temperature, alopecia, rash, increased transaminases.
Potentially Fatal: Delayed and cumulative bone marrow depression.
Drug Interactions
Additive bone marrow suppression with other cytotoxic drugs e.g. vincristine, doxorubicin, mitomycin.
Action
Nimustine, a nitrosourea, is an alkylating antineoplastic agent. It interferes with normal DNA function by alkylating and cross-linking the strands of DNA and possibly by protein modification.
ATC Classification
L01AD06 - nimustine ; Belongs to the class of alkylating agents, nitrosoureas. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on nimustine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in